Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor

被引:21
|
作者
Maguire, Orla [1 ]
Pollock, Catherine [1 ]
Martin, Philip [2 ]
Owen, Andrew [2 ]
Smyth, Thomas [1 ]
Doherty, Declan [1 ]
Campbell, Moray J. [3 ]
McClean, Stephen [1 ]
Thompson, Paul [1 ]
机构
[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland
[2] Univ Liverpool, Dept Pharmacol, Liverpool L69 3GF, Merseyside, England
[3] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
基金
英国生物技术与生命科学研究理事会;
关键词
Vitamin D receptor; Prostate; Metabolism; CYP3A4; CYP3A5; HUMAN LIVER-MICROSOMES; PREGNANE-X-RECEPTOR; CYTOCHROME-P450; 3A4; CANCER CELLS; RADICAL PROSTATECTOMY; CLINICAL PRESENTATION; PROTEASE INHIBITOR; GENE POLYMORPHISMS; IN-VITRO; RISK;
D O I
10.1016/j.mce.2012.08.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We investigated the capacity for vitamin D receptor (VDR) to modulate the expression of CYP3A4 and other genes that may facilitate the oxidative inactivation of androgens such as testosterone and androstanediol within prostate cells. We report that exposure to the active hormonal form of vitamin D markedly increased gene expression of CYP3A4 and CYP3A5 and ultimately achieved levels of intracellular CYP3A enzyme activity within LNCaP prostate cancer cells that were comparable to that observed for Caco2 cells, an established model of CYP3A induction, and resulted in the increased turnover of testosterone to its inactive 6 beta-OH metabolite. We demonstrate that VDR directs CYP3A4 and CYP3A5 expression through binding to distinct regulatory motifs located within the 5' promoter regions of both genes. The current data highlight the potential application of VDR-based treatment regimes as a means to limit the bioavailability of growth-promoting androgens within the tumor microenvironment. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [1] Regulation of CYP3A4 and CYP3A5 Expression in Prostate Cells and Modulation of 'Intracrine' Metabolism of Androgens by Liganded Vitamin D Receptor (VDR).
    Pollock, C.
    Maguire, O.
    Smyth, T.
    McClean, S.
    Martin, P.
    Owen, A.
    Thompson, P.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [2] Statin regulation of CYP3A4 and CYP3A5 expression
    Vieira Willrich, Maria Alice
    Hirata, Mario Hiroyuki
    Crespo Hirata, Rosario Dominguez
    PHARMACOGENOMICS, 2009, 10 (06) : 1017 - 1024
  • [3] Comparative drug metabolism by CYP3A4 and CYP3A5
    Huang, WL
    Lin, YS
    Dai, Y
    Totah, RA
    Calamia, JC
    Thummel, KE
    DRUG METABOLISM REVIEWS, 2003, 35 : 187 - 187
  • [4] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism
    McGraw, Joseph
    Cherney, Mitchell
    Bichler, Katherine
    Gerhardt, Armin
    Nauman, Mirielle
    TOXICOLOGY LETTERS, 2019, 315 : 9 - 13
  • [5] The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine
    Topletz, Ariel R.
    Dennison, Jennifer B.
    Barbuch, Robert J.
    Hadden, Chad E.
    Hall, Stephen D.
    Renbarger, Jamie L.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (09) : 1651 - 1661
  • [6] Differential regulation of human CYP3A4 and CYP3A5 genes in lung cells
    Biggs, JS
    Yost, GS
    DRUG METABOLISM REVIEWS, 2002, 34 : 26 - 26
  • [7] Regulation of human CYP3A4 and CYP3A5 genes in lung cells.
    Biggs, JS
    Raunio, H
    Hakkola, J
    Pelkonen, O
    Yost, GS
    FASEB JOURNAL, 2002, 16 (04): : A180 - A180
  • [8] Expression and localization of CYP3A4 and CYP3A5 in human lung
    Anttila, S
    Hukkanen, J
    Hakkola, J
    Stjernvall, T
    Beaune, P
    Edwards, RJ
    Boobis, AR
    Pelkonen, O
    Raunio, H
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 242 - 249
  • [9] Selective expression of CYP3A5 and not CYP3A4 in human blood
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Thummel, KE
    Watkins, PB
    PHARMACOGENETICS, 1996, 6 (05): : 379 - 385
  • [10] CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer
    Plummer, SJ
    Conti, DV
    Paris, PL
    Curran, AP
    Casey, G
    Witte, JS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (09) : 928 - 932